Please check the individual session for location or broadcast availability.
Frank Y. Lin, MD
Sarah Scollon, MS, CGC
Target Audience and Needs
Pediatric oncologists, geneticists, molecular and anatomic pathologists, surgeons, advanced practice providers, genetic counselors, medical trainees, and other healthcare professionals require regular updates on recent advances in the field of pediatric oncology. A multidisciplinary case approach will be used to interpret clinically significant tumor and germline molecular findings (therapeutic, prognostic, and diagnostic) identified through advanced sequencing platforms. The tumor board aims to expand the knowledge of learners, evaluate advances in pediatric oncology research, implement evidence-based guidelines in clinical practice, enhance the quality of pediatric oncology care, and improve patient outcomes.
Educational methods will include case presentations and panel discussion.
At the conclusion of the sessions, the participants should be able to:
- Apply the results of tumor and germline molecular testing to the diagnosis, prognosis, and treatment of pediatric cancer.
- Demonstrate the expanding role of molecular diagnostics in formulating pediatric precision-oncology treatment strategies.
- Use a multidisciplinary approach to interpret results of molecular diagnostics.
- Appraise the molecular tests currently available in pediatric oncology and recognize the limitations and risks of using them.
Participants may be asked to complete a session evaluation.
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.